Filing Flows › Tarsus Pharmaceuticals (TARS) › Q3 2026 › vs Q2 2026
Tarsus Pharmaceuticals (TARS) Q3 2026 vs Q2 2026 (quarter over quarter)
Tarsus Pharmaceuticals's revenue rose $20.7M (+12%) from $174M in Q2 2026 to $195M in Q3 2026.
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $195M | $174M | $20.7M | +12% |
| Net loss | $668M | $18.6M | $650M | 36× |
| Costs & expenses | $863M | $197M | $666M | +339% |
| Operating costs | $857M | $194M | $663M | +342% |
| Interest & other, net | $1.6M | −$4.1M | $5.7M | — |
| Income tax | $4.6M | $2.7M | $1.9M | +71% |
| Cost of revenue | $13.9M | $12.1M | $1.8M | +15% |
| Research & development | $44.2M | $31.0M | $13.2M | +43% |
| SG&A | $168M | $151M | $17.3M | +11% |
| Operating cash sources | $668M | $18.6M | $650M | 36× |
| Depreciation & amortization | $1.0M | $1.0M | $0 | 0% |
| Share-based compensation | $27.2M | $13.3M | $13.9M | +105% |
| Working capital & other | $634M | $65.5M | $569M | +868% |
| Cash used in operations | $6.0M | −$61.2M | $67.2M | — |
| Net loss absorbed | $668M | $18.6M | $650M | 36× |
Questions
How much did Tarsus Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Tarsus Pharmaceuticals's revenue rose $20.7M (+12%) from $174M in Q2 2026 to $195M in Q3 2026.